Patents by Inventor Louis Licamele

Louis Licamele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of predicting a predisposition to QT prolongation
    Patent number: 10570452
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: February 25, 2020
    Assignee: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 10570453
    Abstract: The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: February 25, 2020
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • Method of predicting a predisposition to QT prolongation
    Patent number: 10563260
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: February 18, 2020
    Assignee: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 10563261
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: February 18, 2020
    Assignee: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20180237857
    Abstract: The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 23, 2018
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20180002758
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 4, 2018
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20180002757
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 4, 2018
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20180002759
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 4, 2018
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Antipsychotic treatment based on SNP genotype
    Patent number: 9458507
    Abstract: The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: October 4, 2016
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE
    Publication number: 20160265060
    Abstract: The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Application
    Filed: March 30, 2016
    Publication date: September 15, 2016
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • Antipsychotic treatment based on SNP genotype
    Patent number: 9328387
    Abstract: The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: May 3, 2016
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20150259747
    Abstract: The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: May 28, 2015
    Publication date: September 17, 2015
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20150225793
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 13, 2015
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20150225795
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 13, 2015
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20150225794
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 13, 2015
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
    Patent number: 9080214
    Abstract: Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction.
    Type: Grant
    Filed: May 17, 2008
    Date of Patent: July 14, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9074255
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9072742
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9074256
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9074254
    Abstract: The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton